Search results
Results from the WOW.Com Content Network
Quest Diagnostics (NYSE: DGX) stock was teasing its all-time high on Thursday, no mean feat for a company that's been publicly traded for decades. The healthcare testing specialist's share price ...
Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report To read this article on Zacks.com click ...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the ...
Let's see if Quest Diagnostics Incorporated (DGX) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam ( whistleblower ) settlement paid by a medical lab for manufacturing and distributing a faulty product. [ 53 ]
Stock name Symbol Country of origin Q2 Holdings, Inc. QTWO: US Qiagen N.V. QGEN: Netherlands: Quad/Graphics, Inc. QUAD: US Quaker Chemical Corporation: KWR: US Quanex Building Products Corporation NX: US Quanta Services Inc. PWR: US Quantum FinTech Acquisition Corporation QFTA: US Quantum FinTech Acquisition Corporation QFTA.UN: US QuantumScape ...
Looking ahead to 2025, Quest Diagnostics projects revenue in the range of $10.70 billion to $10.85 billion, indicating continuous growth. The adjusted diluted EPS guidance stands between $9.55 and ...
Celera Corporation is a subsidiary of Quest Diagnostics which focuses on genetic sequencing and related technologies. It was founded in 1998 as a business unit of Applera , spun off into an independent company in 2008, and finally acquired by Quest Diagnostics in 2011.